Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Aug 05

    Regeneron Reports Second Quarter 2020 Financial and Operating Results
  • Jul 29

    Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas Burners


  • Regeneron Pharmaceuticals Q2 2020 Earnings Conference Call
    Aug 5
    8:30 AM EDT
    Aug 5, 2020 | 8:30 AM EDT